Today’s Research Reports on Stocks to Watch: Ampio Pharmaceuticals and Versartis
NEW YORK, NY / ACCESSWIRE / December 4, 2017 / It was an exciting day for biotech companies Ampio Pharmaceuticals and Versartis. Both stocks had big closes in the green. Ampio has engaged with LaVoieHealthScience for investor and public relations. Versartis did not have any remarkable news to explain the unusual gaining activity.
RDI Initiates Coverage on:
Ampio Pharmaceuticals, Inc.
https://rdinvesting.com/news/?ticker=AMPE
Versartis, Inc.
https://rdinvesting.com/news/?ticker=VSAR
Ampio Pharmaceuticals, Inc. shares skyrocketed this past Friday, closing the day up 21.32% on nearly 2.2 million shares traded. Average trading volume for the stock is just under 1 million shares. The pharmaceutical company announced that it has engaged LaVoieHealthScience for their services in investor and public relations, which will immediately begin designing and executing a strategic communications plan to extend Ampio's reach. The company has lead product called Ampion that is in a phase 3 clinical trial and is intended to treat signs and symptoms of severe osteoarthritis of the knee. CEO Michael Macaluso commented, "As we continue to move forward with Ampion, we believe this is the right time to engage with a strategic communications firm and LHS is the right choice given their deep industry experience. We look forward to working with the LaVoieHealthScience team."
Access RDI's Ampio Pharmaceuticals, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=AMPE
Versartis, Inc. shares were gaining speed on Friday, closing the day up 15.38%. There was no remarkable news to explain the gains. It was at the end of October that the California-based endocrine focused biopharma company reported its third quarter results which were less than thrilling. The company reported a loss of $49.8 million for the period. A loss of $1.40 per share was wider than the loss of 68 cents that analysts on Wall Street had been expecting. The company also said that its phase 3 study of somavaratan in pediatric growth hormone deficiency did not reach its primary endpoint. CEO Jay Shepard commented, "In response to the disappointing outcome of the VELOCITY trial last month, we have been working diligently to understand the results and determine appropriate next steps for the company." The company also recently announced it has hired Cowen to help with evaluating potential transactions. A year ago shares of the stock were over $12, today they are trading slightly over $2.00.
Access RDI's Versartis, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=VSAR
Our Actionable Research on Ampio Pharmaceuticals, Inc. (NYSE: AMPE) and Versartis, Inc. (NASDAQ: VSAR) be downloaded free of charge at Research Driven Investing.
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
CONTACT
For any questions, inquiries, or comments reach out to us directly at:
Address:
Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011
Email:
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: RDInvesting.com
